Home Latest Articles
Latest Articles
  • Xiaoqing WANG, Guangtao XIA
    World Clinical Drug. 2022, 43(1): 11-14.

    In recent years, with the development and clinical application of more and more efficient and safe biological agents, great progress has been made in the treatment of rheumatic immune diseases. As a new biological agent, secukinumab has the characteristics of rapid onset, significant curative effect and high safety. It can significantly improve the prognosis and quality of life of patients. This paper reviewed the application of secukinumab in the treatment of rheumatism, mainly focusing on the application and curative effect of ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and other diseases, in order to provide reference for clinical diagnosis and treatment.

  • Qingling YANG, Guangtao XIA
    World Clinical Drug. 2022, 43(1): 15-18.

    Systemic lupus erythematosus (SLE) is a chronic diffuse connective tissue disease involving multiple systems of the whole body. The etiology and mechanism are not completely clear. At present, the treatment of SLE is still dominated by traditional drugs, such as non steroidal anti-inflammatory drugs, glucocorticoids and immunosuppressants, etc. In recent years, with the continuous improvement of the level of molecular targeted therapy, relevant academic circles have begun to pay extensive attention to biological agent therapy. Compared with traditional treatment methods, biological agents have a selective effect on self reactive lymphocytes or inflammatory mediators, which can reduce the damage of immune function and the incidence of adverse reactions. Belizumab is a medical biological agent and the first inhibitor of B lymphocyte stimulating factor. This paper reviewed the new progress of belizumab in the treatment of SLE, in order to provide reference for clinical diagnosis and treatment.

  • Yong LIU, Xiaoning YAN
    World Clinical Drug. 2022, 43(1): 19-25.
    Objective

    To explore the molecular mechanism of abietic acid in the trearment of psoriasis by using a network pharmacology.

    Methods

    Proteinprotein interaction networks were mapped using STRING database and Cytoscape software. Gene Ontology analysis and Kyoto Encyclopedia of Genes and Genomes analysis of targets were performed on the target with the help of DAVID database. Molecular docking was performed between the core target and abietic acid to verify the binding ability of abietic acid to the core target.

    Results

    Sixty targets for the treatment of psoriasis with abietic acid were screened, mainly tumor necrosis factor (TNF), mitogen-activated protein kinase 3 (MAPK3), tumor protein 53 (TP53) and peroxisome proliferation-activated receptor γ(PPAR). The targets mainly involved in cell zinc ion binding, steroid hormone receptor activity, retinoic acid receptor activity and other biological processes. Peroxisome proliferation-activated receptor (PPAR) signaling pathway and arachidonic acid metabolism signaling pathway are the main action pathways of abietic acid in the treatment of psoriasis.

    Conclusion

    Abietic acid treatment of psoriasis reflects the characteristics of multi-target and multi-pathway. This study provides a scientific basis for further explaining the mechanism of abietic acid in the treatment of psoriasis.

  • Zhiqiang LIU, Yi LIANG, Deli ZENG
    World Clinical Drug. 2022, 43(1): 26-31.
    Objective

    To investigate the efficacy and safety of laprazole sodium for injection in the treatment of peptic ulcer with upper gastrointestinal bleeding.

    Methods

    160 Patients with peptic ulcer complicated with gastrointestinal bleeding admitted to the Medical Oncology of Qionghai People's Hospital from June 2018 to June 2020 were prospectively enrolled and randomly divided into control group and observation group with 80 patients each. The control group was treated with omeprazole sodium for injection and the observation group was treated with laprazole sodium for injection. The effective hemostasis rate of the two groups was observed 72 h after treatment. The proportion of patients undergoing blood transfusion and endoscopic or surgical treatment for gastrointestinal bleeding during the treatment period were observed. The safety of the two groups was evaluated.

    Results

    The effective hemostasis rate at 72 h was 93.75% in the observation group and 92.50% in the control group, and there was no significant difference between the two groups (P>0.05). The effective hemostatic rates of the low-risk subgroup were 94.87% and 94.59% in the observation group and the control group, and the effective hemostatic rates of the high-risk subgroup were 92.68% and 90.69%, respectively, with no statistical significance between the two groups (P>0.05). During the treatment, 1 high-risk patient in both the observation group and the control group changed to endoscopic hemostasis; There was no recurrence of bleeding in both groups within 1 week after treatment. There were 5 patients (6.25%) in the observation group receiving blood transfusion, and 3 patients (3.75%) in the control group receiving blood transfusion, and there was no statistical significance between the two groups (P>0.05). The overall incidence of treatment safety in the observation group was 5.00%, lower than that in the control group (15.00%), and the difference was statistically significant (P<0.05).

    Conclusion

    Eprazole sodium for injection is an ideal drug for the treatment of peptic ulcer complicated with bleeding, which is suitable for clinical application.

  • Jun XU, Yu HE, Feifei YANG, Qian WANG, Xiaobao LI, Siyuan LI
    World Clinical Drug. 2022, 43(1): 32-38.
    Objective

    To compare nalbuphine and sufentanil-based general anesthesia induction in blunting hemodynamic response to tracheal intubation in adult patients.

    Methods

    42 adult patients undergoing elective surgery under general anesthesia were randomly divided into nalbuphine (n=20) and sufentanil group (n=22). General anesthesia was induced with 0.30 mg/kg nalbuphine or 0.30 μg/kg sufentanil, respectively, followed by administration of 2mg/kg propofol and 0.60 mg/kg rocuronium bromide. After intubation, remifentanil and propofol were infused for anesthesia maintaining. 10 min before the end of surgery, patients were administrated with 0.10 mg/kg nalbuphine or 0.10 μg/kg sufentanil, respectively.

    Results

    There was no significant difference in demographic data or hemodynamic data including mean arterial pressure (MAP), systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) between the two groups at time point of baseline and just before induction (P>0.05). Patients from nalbuphine group showed significant higher MAP, SBP, DBP and HR when compared with patients from sufentanil group at the time point of just after intubation, 1 min, 3 mins and 5 mins after intubation and the beginning of surgery (P<0.05). There was lower incidence rate of respiratory depression and dryness of mouth in nalbuphine group when compared with sufentanil group (P<0.05). However, we did not find any difference in the recovery of consciousness, extubation time, numerical pain rating scale, post-anesthesia care unit (PACU) staying time or other adverse events including nausea, vomiting, dizziness and pruritus between two groups (P>0.05).

    Conclusion

    Compared with sufentanil, nalbuphine-based general anesthesia induction and postoperative analgesia can reduce the occurring of hypotension after intubation, and the incidence of respiratory depression and dryness of mouth after extubation in PACU.

  • Weiyan GUO, Yuanji WANG, Shiwan DUAN, Yongwei LI, Juan LYU, Yamei LI
    World Clinical Drug. 2022, 43(1): 39-44.
    Objective

    To analyze the clinical efficacy of recombinant human brain Natriuretic peptide (RH-BNP) in patients with different heart failure, in order to provide more evidence for the clinical application of Rh-BNP.

    Methods

    Using retrospective analysis, for patients with heart failure treated in Xi'an First Hospital from January 2018 to December 2018, the New York Heart Association (NYHA) and Kay were used. Killip's cardiac function was graded, and N-terminal probrain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-cTnT) before and after the use of rh-BNP), creatine kinase isoenzyme (CK-MB), myoglobin (MYO) and other biomarkers level to analyze, record the occurrence of adverse reactions, and analyze the patient's treatment status.

    Results

    The levels of NT-proBNP, hs-cTnT, CK-MB, and MYO in patients with NYHA and Killip cardiac function classification heart failure using rh-BNP were significantly reduced (P<0.05). Comparing the results of treatment between the two groups, NT-proBNP was lower in patients with Killip cardiac function classification heart failure (P<0.05); the levels of hs-cTnT, CK-MB and MYO in patients with NYHA function classification heart failure were lower (P<0.05). There was no significant difference in the incidence of adverse reactions and the effectiveness of treatment between the two groups (P>0.05).

    Conclusion

    rh-BNP is also safe and effective for NYHA and Killip cardiac function grading patients with heart failure, and it is worthy of clinical application.

  • Mengmin XU, Jianye YANG, Feiyan YANG, Wenbin HU, Guobiao YANG
    World Clinical Drug. 2022, 43(1): 45-50.
    Objective

    To evaluate the efficacy and safety of durvalumab combined with chemotherapy as neoadjuvant therapy for patients with locally advanced non-small cell lung cancer (NSCLC).

    Methods

    Thirty-eight patients with operable locally advanced NSCLC were enrolled and received two cycles of neoadjuvant therapy with durvalumab combined with paclitaxel/carboplatin, followed by surgical resection. After postoperative recovery, durvalumab alone or in combination with paclitaxel/carboplatin were administered as adjuvant therapy for at least two cycles. Clinical response rate, pathological response rate, disease-free survival (DFS), overall survival (OS) and adverse events were assessed.

    Results

    After neoadjuvant therapy, the proportions of clinical complete response, partial response, stable disease and disease progression were 0.00%, 65.78%, 31.58% and 2.63%, respectively. The objective response rate (ORR) was 65.78%. Significant pathological response and complete pathological response were 57.89% and 23.68%, respectively. Up to the last follow-up date, three patients (7.89%) relapsed and two patients (5.26%) died. The mean DFS was 15.4 months (95%CI: 14.4-16.3 months), and the mean OS was 15.8 months (95%CI: 15.1 - 16.5 months). The most common adverse events were alopecia (47.37%), nausea and vomiting (42.11%), fatigue (39.47%), anemia (34.21%), neutropenia (28.95%), leukopenia (21.05%) and constipation (21.05%). Most of the adverse events were grade 1 - 2, and only a few were grade 3 - 4.

    Conclusion

    Durvalumab combined with neoadjuvant chemotherapy can achieve a higher pathological response rate and survival benefit in patients with locally advanced NSCLC, and is well tolerated.

  • Dan YANG, Juanjuan XU, Xuan WANG, Yunyun LI, Qiming ZHU
    World Clinical Drug. 2022, 43(1): 51-55.
    Objective

    To study the effects of ticagrelorcombined with ligustrazine hydrochloride on endothelial cell specific molecule-1 (ESM-1), interleukin-1β (IL-1β) andsoluble vascular cell adhesion molecule 1 (sICAM-1) in patients with unstable angina pectoris (UAP).

    Methods

    A total of 113 patients with UAP treated in the department of respiratory and critical care medicine, union hospital, Tongji medical college, Huazhong university of science and technologyfrom February 2019 to February 2020 were selected and divided into combination group (ticagrelor+ligustrazine hydrochloride, n=57) and monotherapy group (ticagrelor, n=56) by random number table method. Both groups took 14 days as a course of treatment, and two courses of treatment were performed in both groups. The clinical efficacy, serum ESM-1, IL-1β, sICAM-1, fibrinogen (FBG), D-dimer (D-D), fibrinogen degradation products (FDP), clinical symptoms and adverse reactions were compared between the two groups.

    Results

    After treatment, the total effective rate was 53 cases (92.98%) in the combined group and 44 cases (78.57%) in the single drug group, and there was significant difference in the total effective rate between the two groups (P<0.05). Serum ESM-1, IL-1β, sICAM-1, D-D and FDP in the two groupsdecreased, and the levels in the combined group were significantly lower than those in the single drug group (P<0.05). The levels of FBG in the two groups increased, and the levels in the combined group were significantly higher than those in the single drug group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).

    Conclusion

    In patients with UAP, ticagrelor combined with ligustrazine hydrochloride has a significant effect, which can effectively improve the serum levels of ESM-1, IL-1β and sICAM-1, which also has good security.

  • Yingjie WANG, Zhuqian JIANG, Zongqin WU, Jie LIU, Ruijing LUO, Shu LI, Weihan CHAI, Yong PENG, Bin LI
    World Clinical Drug. 2022, 43(1): 56-61.
    Objective

    To evaluate the efficacy of nourishing blood and expelling pathogenic factors therapy for psoriasis vulgaris with blood-dryness syndrome and its influence on the expression of serum interleukin17 (IL-17).

    Methods

    Simple random grouping method was used,120 cases of psoriasis were randomly divided into the control group (n=60) and the observation group (n=60). The control group was given the Acitretin Capsule and the observation group was treated with Yangxue Xuantou Decoction. The treatment period was 8 weeks. Psoriasis area and severity index (PASI), TCM syndrome integral, and the levels of IL-17 observed after the treatment in the two groups.

    Results

    The total effective rate of the observation group and the control group was 83.33% and 86.67% respectively, the total effective rate were comparable in two groups (P>0.05). After the treatment, PASI scores, TCM syndrome integral and the levels of IL-17 were all significantly reduced in the two groups (P<0.05), the score of improving TCM syndrome was superior in treatment group to control group (P<0.01), in terms of reductions PASI scores and the levels of IL-17, the difference between the two groups was no statistically significant (P>0.05).

    Conclusion

    Nourishing blood and expelling pathogenic factors therapy is effective for psoriasis with blood-dryness syndrome. The mechanism may be related to the davn-regulation of serum IL-17 expression.

  • Xiaoju XU, Yue YOU, Ming CHEN, Guorong FAN
    World Clinical Drug. 2022, 43(1): 62-69.
    Objective

    To systematically evaluate the effectiveness, safety and economy of capofungin in the treatment of elderly invasive fungal infection (IFI), and to provide evidence-based reference for clinical treatment.

    Methods

    Computer search of PubMed, Cochrane Library, Embase, CNKI, Chinese Journal Full-text Database, VIP and Wanfang Database, etc., collect randomized controlled trials (RCT) of caspofungin in the treatment of elderly IFI, and extract data from literature that meets the inclusion criteria. The modified Jadad scale was used to evaluate the quality of the included literature, the RevMan 5.3 software was used to conduct meta-analysis of the total clinical effectiveness and the incidence of adverse drug reactions, the cost-effectiveness analysis method was used to conduct economic evaluation, and the single-factor sensitivity analysis and Probability sensitivity analysis.

    Results

    A total of 6 RCTs were included, with a total of 551 patients. The results of meta-analysis showed that the total effective rate of patients in the experimental group (caspofungin group) was significantly higher than that of the control group (other drug groups), and the difference was statistically significant [OR=2.54, 95%CI(1.75, 3.69), P<0.001]; There was no significant difference in the incidence of adverse drug reactions between the two groups of patients [OR=0.43, 95%CI(0.16, 1.17), P=0.10]. The pharmacoeconomic evaluation results showed that caspofungin had the highest clinical effectiveness, but the cost is also higher. Caspofungin was always more economical than amphotericin B liposomes, and the increased cost relative to itraconazole, voriconazole and amphotericin B was also within an acceptable range.

    Conclusion

    Caspofungin is effective, safe and economical in the treatment of elderly IFI. However, this conclusion needs to be further verified by more large-sample, high-quality, multi-center RCTs.

News